Journal
CELL STEM CELL
Volume 24, Issue 4, Pages 566-+Publisher
CELL PRESS
DOI: 10.1016/j.stem.2019.02.005
Keywords
-
Categories
Funding
- Japan Agency for Medical Research and Development (AMED) grants for the Core Center for iPS Cell Research, Research Center Network for Realization of Regenerative Medicine
- Japan Society for the Promotion of Science (JSPS) KAKENHI [15H05581]
- Grants-in-Aid for Scientific Research [15H05581] Funding Source: KAKEN
Ask authors/readers for more resources
Induced pluripotent stem cells (iPSCs) have strong potential in regenerative medicine applications; however, immune rejection caused by HLA mismatching is a concern. B2M gene knockout and HLA-homozygous iPSC stocks can address this issue, but the former approach may induce NK cell activity and fail to present antigens, and it is challenging to recruit rare donors for the latter method. Here, we show two genome-editing strategies for making immunocompatible donor iPSCs. First, we generated HLA pseudo-homozygous iPSCs with allele-specific editing of HLA heterozygous iPSCs. Second, we generated HLA-C-retained iPSCs by disrupting both HLA-A and -B alleles to suppress the NK cell response while maintaining antigen presentation. HLA-C-retained iPSCs could evade T cells and NK cells in vitro and in vivo. We estimated that 12 lines of HLA-C-retained iPSCs combined with HLA-class II knockout are immunologically compatible with >90% of the world's population, greatly facilitating iPSC-based regenerative medicine applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available